Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ART001
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AccurEdit’s ART001 Gene Editing Drug gets FDA Orphan Designation
Details : ART001, which utilizes LNP technology for targeted gene editing, is designed for the treatment of transthyretin amyloidosis (ATTR), a rare and life-threatening disease.
Product Name : ART001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : ART001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : N1-109
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : N1 Life
Deal Size : Undisclosed
Deal Type : Partnership
Details : The N1 Life has accumulated years of research and development experience in novel delivery systems including their preclinical asset N1-109. With this partnership, both compamies will be accelerating the drug delivery technologies from "bench to bed" to ...
Product Name : N1-109
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 13, 2022
Lead Product(s) : N1-109
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : N1 Life
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
